--- title: "Trofinetide | PepTracker Pro" url: https://peptrackerpro.com/peptides/trofinetide description: "A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Trofinetide High Evidence A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization. Aliases Daybue +6 more Evidence High Evidence Last Updated 2026-07-19 Reading Time 5 min ## What It Is Trofinetide (development code NNZ-2566; Acadia Pharmaceuticals, brand name Daybue) is a synthetic analog of glycine-proline-glutamate (GPE, also called glypromate), the naturally occurring N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). It is the first drug ever approved for Rett syndrome, a rare and severe neurodevelopmental disorder caused almost entirely by loss-of-function mutations in the X-linked gene MECP2. Rett syndrome affects predominantly girls (roughly 1 in 10,000-15,000 female births); after a period of apparently normal early development, children undergo a regression that costs them purposeful hand use and spoken language and leaves them with stereotypic hand movements, gait and breathing abnormalities, seizures and profound communication impairment. Because MECP2 sits at the top of a broad gene-regulation network, its loss disturbs synapse formation and maturation, glial function and neuroinflammatory tone rather than a single pathway - which is why a small, pleiotropic peptide is an attractive therapeutic strategy. Native GPE is cleaved from IGF-1 and has neurotrophic and neuroprotective activity, but it is metabolically unstable; trofinetide is engineered (a 2-methylproline substitution) to resist breakdown and achieve drug-like exposure. It is given as a weight-based oral solution twice daily. In the pivotal 12-week placebo-controlled Phase 3 LAVENDER trial of 187 girls and young women aged 5-20, trofinetide produced statistically significant improvement over placebo on both co-primary endpoints - the caregiver-rated Rett Syndrome Behaviour Questionnaire (RSBQ) and the clinician-rated Clinical Global Impression-Improvement (CGI-I) - leading to FDA approval on March 10, 2023 for patients 2 years and older. Open-label extension studies (LILAC, LILAC-2) and the real-world LOTUS study support durable benefit, and gastrointestinal tolerability (diarrhea and vomiting) is the main practical limitation. Trofinetide is a physician-prescribed medicine, not a self-sourced research chemical. In 2026 the program advanced on two fronts: the FDA approved Daybue STIX, a dye- and preservative-free powder formulation that became broadly available in April 2026, and in June 2026 the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion after re-examination, recommending marketing authorization in Europe. Also known as: Daybue, DAYBUE, NNZ-2566, glypromate analog, GPE analog, glycyl-2-methylprolyl-glutamate, IGF-1 (1-3) analog ## Regulatory Status FDA-approved (prescription) for Rett syndrome in adults and children 2 years and older Trofinetide (Daybue, Acadia Pharmaceuticals) received FDA approval on March 10, 2023 as the first and only treatment for Rett syndrome, indicated for adults and pediatric patients 2 years of age and older. In December 2025 the FDA approved Daybue STIX, a dye- and preservative-free powder formulation, which became broadly available to U.S. families in April 2026. In June 2026 the EMA's CHMP adopted a positive opinion (following re-examination) recommending marketing authorization in the EU. It is a specialist-prescribed oral medicine; any vendor selling 'trofinetide' or 'NNZ-2566' powder for self-use is illegitimate. Effective: July 2026 View FDA Source (https://en.wikipedia.org/wiki/Trofinetide) ## Why Researchers Study It Trofinetide is a landmark case in peptide therapeutics for two reasons. First, it is the first medicine of any kind approved for Rett syndrome - a disorder that, because it stems from loss of a master gene-regulator (MECP2), had long been considered too pleiotropic to drug. Rather than trying to replace MECP2 or fix a single broken pathway, trofinetide takes a 'restore the tone' approach: it mimics a tiny endogenous fragment of IGF-1 (the tripeptide GPE) that has broad neurotrophic and anti-inflammatory activity, nudging many downstream processes - synaptic maturation, dendritic health, microglial and astrocytic activation, and inflammatory-cytokine output - back toward normal at once. Second, it is a clean example of medicinal-chemistry stabilization of a fragile natural peptide: native GPE is metabolically short-lived, and a single methyl-proline substitution converts it into an orally dosable drug. For peptide scientists, trofinetide is a template for treating neurodevelopmental and neurodegenerative conditions with small, multi-target neuropeptide analogs, and it has renewed interest in the IGF-1/GPE axis (which overlaps with other neurotrophic strategies such as davunetide, cerebrolysin and dihexa) as a druggable target. ## Proposed Mechanisms - Synthetic analog of glycine-proline-glutamate (GPE / glypromate), the N-terminal tripeptide naturally cleaved from IGF-1, stabilized by a 2-methylproline substitution for oral, drug-like exposure - Thought to increase the availability and activity of IGF-1-pathway signaling, supporting neuronal survival, dendritic and synaptic maturation - Reduces production of pro-inflammatory cytokines and dampens neuroinflammation in the central nervous system - Normalizes the overactivation of microglia and astrocytes (glial cells) implicated in Rett syndrome pathology - Promotes synaptic and dendritic health downstream of MECP2 loss rather than correcting the underlying genetic mutation - Acts as a small, pleiotropic (multi-target) neurotrophic peptide - restoring signaling tone across several pathways instead of blocking a single receptor ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | RCT (human, Phase 3 - pivotal) | Rett syndrome - LAVENDER: 187 girls/young women aged 5-20, oral trofinetide vs placebo over 12 weeks | Statistically significant improvement over placebo on both co-primary endpoints - the caregiver-rated Rett Syndrome Behaviour Questionnaire (RSBQ) and clinician-rated Clinical Global Impression-Improvement (CGI-I); basis for FDA approval | Source: https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome/ | | Regulatory milestone | Rett syndrome (Acadia Pharmaceuticals) | FDA approval March 10, 2023 - first and only treatment for Rett syndrome, for adults and children 2+; dye/preservative-free Daybue STIX approved Dec 2025 (broadly available April 2026); EMA CHMP positive opinion June 2026 | Source: https://en.wikipedia.org/wiki/Trofinetide | | Real-world / long-term evidence | Rett syndrome - LOTUS real-world study, 277 people living with Rett syndrome, up to 12 months of treatment | Caregiver-reported improvements across behavior, nonverbal communication, alertness and social interaction; diarrhea was the most common GI adverse event (reported in ~23-50% early); published in Developmental Medicine & Child Neurology | Source: https://acadia.com/en-us/media/news-releases/real-world-data-lotus-study-evaluating-long-term-efficacy-and | | Real-world treatment landscape (2026) | Rett syndrome - U.S. cohort comparing individuals treated vs untreated with trofinetide | Characterized demographic and clinical profiles of trofinetide-treated versus untreated patients in routine practice, informing real-world uptake and management; published 2026 | Source: https://jheor.org/article/162589-real-world-treatment-landscape-of-individuals-with-rett-syndrome-treated-and-untreated-with-trofinetide-in-the-united-states | ## Commonly Discussed Benefits Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Researching Trofinetide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=trofinetide) ## Safety & Cautions - Approved specifically for Rett syndrome; it treats neurobehavioral symptoms and does not correct the underlying MECP2 mutation or cure the disorder - it is disease-managing, not disease-reversing - Gastrointestinal side effects are common and are the main practical limitation: diarrhea (very common, reported in a large share of patients) and vomiting can cause dehydration and weight loss and sometimes lead to dose reduction or discontinuation; caregivers are counseled on diarrhea management and stopping certain anti-diarrheal-conflicting medicines - A physician-prescribed oral medicine given under specialist (neurology/genetics) supervision as a weight-based solution twice daily - not a self-administered 'research peptide.' Any vendor selling 'trofinetide' or 'NNZ-2566' powder is illegitimate and unsafe - Dosing is by body weight and requires the correct volume twice daily; the newer Daybue STIX powder is dye- and preservative-free but is still a prescription formulation prepared per label instructions - Approved based on 12-week neurobehavioral endpoints (RSBQ and CGI-I); longer-term effects on core function, seizures and disease trajectory continue to be characterized in extension (LILAC/LILAC-2) and real-world (LOTUS) studies - Not medical advice. Eligibility, dosing, GI monitoring and management are individualized decisions made by a qualified clinician ## Comparisons See how Trofinetide compares to related peptides: Trofinetide vs Cerebrolysin: https://peptrackerpro.com/compare/trofinetide-vs-cerebrolysin Trofinetide vs Davunetide: https://peptrackerpro.com/compare/trofinetide-vs-davunetide Trofinetide vs Dihexa: https://peptrackerpro.com/compare/trofinetide-vs-dihexa Trofinetide vs Palopegteriparatide: https://peptrackerpro.com/compare/trofinetide-vs-palopegteriparatide Trofinetide vs Trontinemab: https://peptrackerpro.com/compare/trofinetide-vs-trontinemab ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Trofinetide - Wikipedia PubMed (https://en.wikipedia.org/wiki/Trofinetide) 2. [2] Development of trofinetide for the treatment of Rett syndrome: from bench to bedside - PMC PubMed (https://pmc.ncbi.nlm.nih.gov/articles/PMC10839050/) 3. [3] Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 LAVENDER Trial of Trofinetide in Rett Syndrome PubMed (https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome/) 4. [4] Real-World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability of DAYBUE (trofinetide) Published in Developmental Medicine & Child Neurology - Acadia PubMed (https://acadia.com/en-us/media/news-releases/real-world-data-lotus-study-evaluating-long-term-efficacy-and) 5. [5] Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States - JHEOR (2026) PubMed (https://jheor.org/article/162589-real-world-treatment-landscape-of-individuals-with-rett-syndrome-treated-and-untreated-with-trofinetide-in-the-united-states) ### Keep researching in the app - Log Trofinetide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=trofinetide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Cerebrolysin Medium Evidence A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions. Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Cognition: https://peptrackerpro.com/benefits/cognition Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/cerebrolysin \+ Compare: https://peptrackerpro.com/compare?select=cerebrolysin Track in App: https://app.peptrackerpro.com/?add=cerebrolysin ### Davunetide Low Evidence An eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/davunetide \+ Compare: https://peptrackerpro.com/compare?select=davunetide Track in App: https://app.peptrackerpro.com/?add=davunetide ### Dihexa Low Evidence A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/dihexa \+ Compare: https://peptrackerpro.com/compare?select=dihexa Track in App: https://app.peptrackerpro.com/?add=dihexa ### Palopegteriparatide High Evidence Palopegteriparatide (Yorvipath, developed as TransCon PTH) is Ascendis Pharma's once-daily prodrug of parathyroid hormone (1-34). An inert methoxy-PEG carrier is attached to PTH(1-34) through a TransCon linker that auto-cleaves at physiologic pH and temperature, releasing unmodified native-sequence PTH slowly enough to hold hormone levels inside the physiologic range for a full 24 hours. It is the first therapy approved as a true hormone replacement for chronic hypoparathyroidism rather than as an add-on to calcium and active vitamin D: in the Phase 3 PaTHway trial 78.7% of treated adults met a composite endpoint of normal serum calcium plus independence from conventional therapy at week 26, versus 4.8% on placebo. The FDA approved Yorvipath on August 9, 2024. Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Hormone Support (https://peptrackerpro.com/benefits/hormone-support)Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/palopegteriparatide \+ Compare: https://peptrackerpro.com/compare?select=palopegteriparatide Track in App: https://app.peptrackerpro.com/?add=palopegteriparatide ### Trontinemab Medium Evidence An investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. View Details: https://peptrackerpro.com/peptides/trontinemab \+ Compare: https://peptrackerpro.com/compare?select=trontinemab Track in App: https://app.peptrackerpro.com/?add=trontinemab ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Trofinetide", "description": "A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization.", "url": "https://peptrackerpro.com/peptides/trofinetide", "lastReviewed": "2026-07-19", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Trofinetide", "item": "https://peptrackerpro.com/peptides/trofinetide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Parents and clinicians of individuals with Rett syndrome weighing the first approved therapy, its neurobehavioral benefits, and how to manage the gastrointestinal side effects?", "acceptedAnswer": { "@type": "Answer", "text": "Trofinetide is a research peptide studied in preclinical models. A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization." } }, { "@type": "Question", "name": "Researchers studying the IGF-1 / GPE (glypromate) axis and small neurotrophic peptides as treatments for neurodevelopmental and neurodegenerative disorders?", "acceptedAnswer": { "@type": "Answer", "text": "Trofinetide is a research peptide studied in preclinical models. A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization." } }, { "@type": "Question", "name": "Peptide scientists interested in how an unstable endogenous tripeptide was converted into an orally dosable drug and how a pleiotropic 'restore-the-tone' peptide can treat a disorder driven by loss of a master gene-regulator?", "acceptedAnswer": { "@type": "Answer", "text": "Trofinetide is a research peptide studied in preclinical models. A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization." } } ] } ] ```